ArticleCureus2025
Influence of Diabetes Mellitus on Metabolic and Hormonal Interactions Promoting Aggressive Prostate Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Diabetes mellitus might play a vital role in promoting prostate cancer development, progression, and aggressiveness. The influence of diabetes on prostate cancer outcomes has long been debated. However, the mechanism through which diabetes mediates its effect on prostate cancer development and progression has not been established. This study aimed to study the influence of diabetes mellitus on prostate cancer outcome and aggressiveness. Material and methods This study includes 100 patients newly diagnosed with benign prostatic hyperplasia (BPH) and 200 patients with histologically confirmed prostate adenocarcinoma, of which 100 were diabetic. Descriptive statistics were performed to analyse and summarize the results as mean±standard deviation (SD). Statistically significant differences between two or more groups were determined using ANOVA and the post hoc Tukey test. Chi-square test was performed to compare the distribution of tumor grades and risk categories between patients with prostate cancer with diabetes and without diabetes. Correlation analyses were performed to analyse the association of metabolic and hormonal parameters among themselves and cancer grade. Multiple linear regression analysis was done to analyse the relationship of hormone profile with the risk of prostate cancer in men with and without diabetes. Results Data showed that serum insulin and IGF-1 were significantly elevated in prostate cancer, highest being in prostate cancer with diabetes, and they had a positive association with prostate cancer Gleason score, grade, and high risk. Lipid profile and HbA1c also had a significant association with prostate cancer Gleason score and grade. Men with diabetes and prostate cancer were diagnosed with higher-grade and high-risk cancer than men with prostate cancer but without diabetes. Conclusion This study confirms the influence of diabetes on metabolic and hormonal parameters, particularly serum HbA1c, insulin, IGF1, and prostate-specific antigen, which are positively associated with higher grade and high risk, thus leading to the development and promotion of aggressive cancer in patients with coincidental diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.